Nihal M, Mikkola D, Wood G S
Department of Dermatology and the Skin Diseases Research Center, Case Western Reserve University, Cleveland, Ohio, USA.
J Mol Diagn. 2000 Feb;2(1):5-10. doi: 10.1016/S1525-1578(10)60609-5.
A monoclonal B cell population is the hallmark of B cell neoplasms including cutaneous B cell lymphomas (CBCLs). We modified and tested several polymerase chain reaction (PCR)-based assays involving amplification of immunoglobulin heavy chain (IgH) gene rearrangements to optimize assays specifically for cutaneous lymphoid infiltrates. We achieved greatest sensitivity with an assay employing IgH consensus primers complementary to the framework 3 portion of the upstream variable region and the downstream joining region. We studied 12 CBCLs, 6 nodal lymphomas and 7 cell lines. In 17/25 of these B cell neoplasms (84%), we detected one or two dominant bands, consistent with one or both IgH alleles being rearranged in the neoplastic B cell clone. As expected, IgH PCR assays produced diffuse smears in agarose gels or complex ladders in polyacrylamide gels when polyclonal B cell controls (blood and tonsil) were analyzed. However, in normal skin and non-CBCL skin lesions, one or a small number of discrete bands were sometimes detected. In certain cases, this made it difficult to distinguish true positives (monoclonal CBCL) from false positives (clonally restricted benign B cells). Correlation with immunophenotyping confirmed that false positive results were confined to samples with sparse or immunohistologically undetectable B cell infiltrates. Pseudoclonal bands showed variable sizes in repeat PCR reactions and could be distinguished from monoclonal bands by polyacrylamide gel electrophoresis of pooled triplicate PCR products. These findings suggest that molecular diagnosis using IgH PCR assays is best suited for B-cell-rich infiltrates, and can be problematic when applied to suspected T-cell-rich CBCLs, cutaneous T cell lymphomas, or other lesions containing only few B cells unless one is cognizant of the potential pitfalls. Furthermore, these results demonstrate the presence of rare B cells in normal skin and immunohistologically defined cutaneous T cell infiltrates. This correlates with recent reports of sparse B cells within the lymph draining from normal skin and may represent molecular evidence for a trafficking B cell component of the skin-associated lymphoid tissue (SALT). It also suggests a candidate B cell subset for the pathogenesis of cutaneous lymphoid hyperplasia and CBCLs.
单克隆B细胞群体是包括皮肤B细胞淋巴瘤(CBCL)在内的B细胞肿瘤的标志。我们改良并测试了几种基于聚合酶链反应(PCR)的检测方法,这些方法涉及免疫球蛋白重链(IgH)基因重排的扩增,以优化专门针对皮肤淋巴浸润的检测方法。我们使用一种检测方法获得了最高灵敏度,该方法采用与上游可变区框架3部分和下游连接区互补的IgH共有引物。我们研究了12例CBCL、6例淋巴结淋巴瘤和7个细胞系。在这些B细胞肿瘤中的17/25例(84%)中,我们检测到一条或两条优势条带,这与肿瘤性B细胞克隆中一个或两个IgH等位基因发生重排一致。正如预期的那样,当分析多克隆B细胞对照(血液和扁桃体)时,IgH PCR检测在琼脂糖凝胶中产生弥散性条带,或在聚丙烯酰胺凝胶中产生复杂的条带梯。然而,在正常皮肤和非CBCL皮肤病变中,有时会检测到一条或少量离散条带。在某些情况下,这使得难以区分真正的阳性(单克隆CBCL)和假阳性(克隆性受限的良性B细胞)。与免疫表型分析的相关性证实,假阳性结果仅限于B细胞浸润稀疏或免疫组织学上无法检测到的样本。假克隆条带在重复PCR反应中显示出可变大小,并且可以通过对一式三份PCR产物混合后的聚丙烯酰胺凝胶电泳与单克隆条带区分开来。这些发现表明,使用IgH PCR检测进行分子诊断最适合于富含B细胞的浸润,当应用于疑似富含T细胞的CBCL、皮肤T细胞淋巴瘤或其他仅含有少量B细胞的病变时可能会出现问题,除非人们认识到潜在的陷阱。此外,这些结果证明了正常皮肤和免疫组织学定义的皮肤T细胞浸润中存在罕见的B细胞。这与最近关于正常皮肤引流淋巴结中存在稀疏B细胞的报道相关,并且可能代表皮肤相关淋巴组织(SALT)中游走B细胞成分的分子证据。它还提示了皮肤淋巴组织增生和CBCL发病机制的候选B细胞亚群。